Samsung Biologics is enhancing its competitive edge in early drug development by presenting its organoid-based drug discovery research at the prestigious American Association for Cancer Research (AACR) conference. This event, recognized as the largest cancer research meeting globally, serves as a critical platform for advancing preclinical research, demonstrating the company’s commitment to improving clinical predictability through innovative organoid technology derived from patient cells.
Key Highlights from the AACR
The AACR conference, taking place in San Diego, attracts over 22,000 attendees from approximately 140 countries. It stands among the top three cancer research gatherings worldwide, alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). Samsung Biologics, participating in this event for the first time, will present its findings related to “Samsung Organoids.” This unique technology mimics the structure and function of actual organs, providing a superior platform for drug development that aligns more closely with clinical outcomes compared to traditional animal models.
Presentations and Research Outcomes
On the 21st of the conference, Alexis Santana, the Organoid Sales Director, will conduct an oral presentation detailing the promising results of the “Samsung Organoids” research. This presentation will highlight a significant correlation between clinical outcomes and data reflective of patients’ genetic profiles and drug responses. Additionally, a poster session will showcase the efficiency and therapeutic potential of the company’s bispecific antibody platform, “S-DUAL.”
Strategic Focus on Early-Stage Development
Samsung Biologics aims to attract early-stage development clients by leveraging the AACR’s focus on preclinical research. The company is committed to establishing long-lasting relationships with clients by employing an “early lock-in” strategy. This approach encourages collaboration from the onset of drug development, where the need for contract research (CRO) and contract development (CDO) services is particularly high, and extends through to commercial production.
Expanding the Business Model
To enhance its service offerings, Samsung Biologics is evolving from a contract manufacturing organization (CMO) to a more comprehensive model that includes CRO and CDO capabilities, culminating in a “CRDMO” framework. Following the introduction of its organoid-based CRO services last year, the company has further strengthened its CDO capabilities by integrating master cell bank (MCB) production and vector manufacturing into its operations. This comprehensive service model is designed to meet client demands across the entire spectrum of drug development, from initial candidate discovery to commercial launch.
Commitment to Client Collaboration
Jung Hyung-nam, Executive Vice President and Head of the Bio Research Institute at Samsung Biologics, expressed the company’s dedication to collaborating with clients from the earliest stages of research. This partnership aims to position Samsung Biologics as a trusted ally throughout the drug development journey. The company is focused on expanding its customized services to address the specific needs of its clients.
Conclusion
Samsung Biologics’ participation in the AACR conference marks a significant milestone in its journey towards redefining drug development through organoid technology. By establishing a robust CRDMO framework and fostering early-stage client relationships, the company is poised to lead in the evolving landscape of biopharmaceutical innovation. The integration of patient-derived organoids into research not only enhances predictability but also sets a new standard for preclinical testing.
- Key Takeaways:
- Samsung Biologics presents organoid-based drug discovery at AACR.
- The company focuses on improving clinical predictability through patient-derived models.
- A CRDMO framework allows comprehensive support from drug discovery to commercialization.
- Early-stage collaboration strategies aim to build long-term client relationships.
- The innovative approach positions Samsung Biologics as a leader in biopharmaceutical development.
Read more → en.sedaily.com